Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis.

Autor:	Hong, M1, Wu, Q1, Hu, C1, Fang, J1, You, Y1, Zhong, Z1, Zou, P1, Hu, Y1, Xia, L1
Zdroj:	Bone Marrow Transplantation. Feb2012, Vol. 47 Issue 2, p196-202. 7p. 3 Charts, 1 Graph.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu